Expert Opinion on Drug Safety

Papers
(The TQCC of Expert Opinion on Drug Safety is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future53
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety50
Long-term safety of ketamine and esketamine in treatment of depression47
Gastrointestinal and cardiovascular adverse events associated with NSAIDs44
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients42
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients38
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system38
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects35
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines34
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database31
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia30
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion28
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis27
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)26
Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis26
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma26
The therapeutic potential of psilocybin: a systematic review24
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation24
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge24
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review23
Current and emerging long-acting antipsychotics for the treatment of schizophrenia23
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data21
Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions21
Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium20
Antimicrobial resistance and the post antibiotic era: better late than never effort19
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism19
Gastroenterological safety of IL-17 inhibitors: a systematic literature review19
Tafenoquine: a toxicity overview18
Thalidomide: history, withdrawal, renaissance, and safety concerns18
Deprescribing in migraine18
The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability18
Safety and efficacy of P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary interventions18
Current strategies for managing intestinal failure-associated liver disease16
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-a16
Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study16
Risks and benefits of reducing the number of drugs to treat HIV-1 infection16
Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions16
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges16
Safety and tolerability of spesolimab in patients with ulcerative colitis15
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings15
Oral isotretinoin for acne: a complete overview15
Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system14
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles14
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system14
Improving the safety of intravenous iron treatments for patients with chronic kidney disease14
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study14
Evaluating safety in hyaluronic acid lip injections14
Safety of dupilumab in patients with atopic dermatitis: expert opinion13
A systematic review on pediatric medication errors by parents or caregivers at home13
Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization13
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis13
Safety and tolerability of preventive treatment options for chronic migraine13
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids13
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy12
The safety of current pharmacotherapeutic strategies for osteosarcoma12
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness12
Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness12
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation12
A long-term open-label safety study of galcanezumab in Japanese patients with migraine12
The effect of patient sex on the efficacy and safety of anticancer immunotherapy12
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?11
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review11
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal11
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection11
Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry11
Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products11
Systematic review and meta-analysis on the safety of dalbavancin11
Expert opinion on sonidegib efficacy, safety and tolerability11
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia11
Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)11
The safety of JAK kinase inhibitors for the treatment of myelofibrosis10
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis10
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability10
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study10
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs10
Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands10
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management10
Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system9
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine9
A review of hydroxyurea-related cutaneous adverse events9
Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system9
Underreporting of Adverse Drug Events: a Look into the Extent, Causes, and Potential Solutions9
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension9
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom9
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions9
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment9
Safety of topical interventions for the treatment of actinic keratosis9
Can ketamine be a safe option for treatment-resistant bipolar depression?9
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors9
Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics9
How can we manage the cardiac toxicity of immune checkpoint inhibitors?9
Cardiovascular risks associated with protease inhibitors for the treatment of HIV8
Safety of intranasal corticosteroids for allergic rhinitis in children8
Safety considerations when managing gastro-esophageal reflux disease in infants8
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis8
Introducing sexual dysfunction in mental care8
A safety review of approved intrathecal analgesics for chronic pain management8
Trends and concerns of potentially inappropriate medication use in patients with cardiovascular diseases8
A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain8
Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data8
A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review8
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections8
Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome8
Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients8
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting8
Effectiveness and sustainability of deprescribing for hospitalized older patients near end of life: a systematic review7
The safety of oral antifungals for the treatment of onychomycosis7
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial7
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU7
Safety of treatment options available for postoperative pain7
Defining and enhancing collaboration between community pharmacists and primary care providers to improve medication safety7
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective7
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs7
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine7
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus7
Novel uses of ketamine in the emergency department7
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer7
Resident and family engagement in medication management in aged care facilities: a systematic review7
Hepatotoxicity of FDA-approved small molecule kinase inhibitors7
Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)7
Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease7
Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review7
Safety of current treatments for paroxysmal nocturnal hemoglobinuria7
Effect of drug interactions between carbapenems and valproate on serum valproate concentration: a systematic review and meta-analysis7
A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy7
Cardiac adverse effects of antiseizure medications7
An inter-professional student-run medication review programme. Reducing adverse drug reactions in a memory outpatient clinic: a controlled clinical trial7
Combining two CGRP inhibitors to treat migraine7
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides7
Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis7
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome7
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions7
Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials7
Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review7
Medication errors during a pandemic: what have we learnt?7
Adverse events in long-term studies of exogenous melatonin7
A review of potential neuropathological changes associated with ketamine7
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents7
Craving and addictive potential of esketamine as side effects?6
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting6
Phenytoin and damage to the cerebellum – a systematic review of published cases6
Safety of secukinumab for the treatment of active ankylosing spondylitis6
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?6
Anti-inflammatory strategies for atherosclerotic artery disease6
Effect of Acetaminophen use during pregnancy on adverse pregnancy outcomes: a systematic review and meta-analysis6
A comparative review of current topical antibiotics for impetigo6
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review6
The safety of available treatment options for short bowel syndrome and unmet needs6
Safety of treating acute liver injury and failure6
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma6
Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data6
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies6
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability6
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system6
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS databas6
Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)6
The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical Trials6
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy6
Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study5
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!5
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies5
The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn5
Associations between hyper-polypharmacy and potentially inappropriate prescribing with clinical and functional outcomes in older adults5
Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease5
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals5
Drug induced stuttering: pharmacovigilance data5
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system5
Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin5
Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis5
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance5
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis5
Assessment of suspected adverse drug reactions in elderly patients with diabetes mellitus based on a Portuguese spontaneous reporting database: analysis of reporting from 2008 to 20185
Safety of current immune checkpoint inhibitors in non-small cell lung cancer5
New approaches to antipsychotic medication adherence – safety, tolerability and acceptability5
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency5
Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey5
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)5
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis5
A safety review of current monoclonal antibodies used to treat multiple sclerosis5
Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research5
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials5
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease5
Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature5
Safety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy5
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management5
Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System5
Bosutinib – related pleural effusion in patients with chronic myeloid leukemia5
Methods for the detection of adverse drug reactions in hospitalized children: a systematic review5
Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy5
A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy5
Safety considerations of current drug treatment strategies for nosocomial pneumonia5
Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study5
Safety of non-hormonal medications for managing hot flashes5
Post-marketing safety surveillance of erenumab: new insight from Eudravigilance5
Improving the data quality of spontaneous ADR reports: a practical example from Malta5
0.052464008331299